Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Retinal Disorder Treatment Industry?

The market for treating retinal disorders has seen robust growth recently. It is projected to expand from $12.59 billion in 2024 to $13.69 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.7%. The past growth can be credited to several factors such as the advent of anti-VEGF therapies, an aging population, a rise in retinal disorder cases, enhanced early detection diagnostic tools, raised awareness and screening initiatives, and wider accessibility to healthcare services.

Predictions show a robust upswing in the retinal disorder treatment market size over the forthcoming years, potentially reaching $19.3 billion by 2029 with a compound annual growth rate (CAGR) of 9.0%. Contributing factors to this upward trend during the projection period may include the focus on patient-oriented retinal healthcare, an increase in worldwide healthcare spending, heightened attention on combined therapies for retinal ailments, an uptick in at-home retinal disorder monitoring, a rise in use of implantable tools for retinal treatments, and the embracement of regenerative medical practices in retinal therapy. Forecasts for the period also suggest key trends like progress in eye imaging technologies, the introduction of minor surgical procedures, the application of artificial intelligence in diagnosis, improved drug delivery systems, the incorporation of virtual reality in retinal recuperation, collaborative efforts between research establishments and pharmaceutical firms, and the progression of gene therapies in tackling inherited retinal disorders.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12701&type=smp

#Which Factors Are Currently Driving The Growth Of The Retinal Disorder Treatment Market?

As the occurrence of retinal diseases increases, the retinal disorder treatment market is forecasted to expand. Retinal diseases, which affect the retina and the light-sensitive tissue at the back of the eye leading to vision loss or substantial visual impairment, can be controlled and their symptoms reduced with treatments such as laser therapy, vitrectomy, and retinal implants. For example, in January 2023, the International Agency for the Prevention of Blindness, an organization based in the UK, predicted that age-related macular degeneration (AMD) would account for 5% of global blindness. Moreover, AMD is expected to influence around 288 million individuals by 2040. Thus, the escalating occurrence of retinal disorders is fueling the growth of the market for retinal disorder treatments.

How Is The Global Retinal Disorder Treatment Market Structured In Terms Of Segments?

The retinal disorder treatment market covered in this report is segmented –

1) By Type: Macular Degeneration, Diabetic Retinopathy, Other Types

2) By Dosage Form: Gels, Eye Solutions, Capsules And Tablets, Eye Drops, Ointments

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration

2) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy

3) By Other Types: Retinal Detachment, Retinitis Pigmentosa, Uveitis, Other Retinal Disorders

What Trends Are Currently Influencing Growth In The Retinal Disorder Treatment Market?

One significant trend emerging in the rare kidney disease market is product innovation. Major contenders in the market focus on producing novel products as a means of solidifying their market position. For example, in September 2022, STADA Arzneimittel AG, a company based in Germany specializing in generics, specialty pharma, and over-the-counter consumer healthcare products, launched Kinpeygo (budesonide), making it the first official EU-authorised drug for the rare kidney condition known as immunoglobulin A nephropathy (IgAN). The EU’s first and only approved treatment for primary IgAN is these modified-release budesonide capsules, a scarce, progressive autoimmune kidney disease where there’s a high unfulfilled need, with around 25%-30% of patients eventually progressing to terminal kidney insufficiency necessitating dialysis or a kidney transplant.

Who Are The Main Participants Shaping The Retinal Disorder Treatment Market Landscape?

Major companies operating in the retinal disorder treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Adverum Biotechnologies Inc., Kodiak Sciences Inc., Acucela Inc., IVERIC bio Inc., Oxurion NV, Graybug Vision Inc., Icon Bioscience Inc., Clearside Biomedical Inc., Aerpio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Opthea Limited, PanOptica Inc., ThromboGenics NV

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Which Region Currently Holds The Largest Share In The Retinal Disorder Treatment Market?

North America was the largest region in the retinal disorder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12701&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model